127 related articles for article (PubMed ID: 3513562)
1. Doxorubicin cardiac toxicity manifesting seven years after treatment. Case report and review.
Freter CE; Lee TC; Billingham ME; Chak L; Bristow MR
Am J Med; 1986 Mar; 80(3):483-5. PubMed ID: 3513562
[TBL] [Abstract][Full Text] [Related]
2. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468
[TBL] [Abstract][Full Text] [Related]
3. Cardiac magnetic resonance imaging for the assessment of the myocardium after doxorubicin-based chemotherapy.
Lunning MA; Kutty S; Rome ET; Li L; Padiyath A; Loberiza F; Bociek RG; Bierman PJ; Vose JM; Armitage JO; Porter TR
Am J Clin Oncol; 2015 Aug; 38(4):377-81. PubMed ID: 24192805
[TBL] [Abstract][Full Text] [Related]
4. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphism at
Bashash M; Connors JM; Gascoyne RD; Meissner B; Schuetz JM; Leach S; Slack GW; Berry BR; Hu H; Sehn LH; Brooks-Wilson AR; Spinelli JJ
Haematologica; 2017 May; 102(5):e199-e202. PubMed ID: 28154089
[No Abstract] [Full Text] [Related]
6. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage.
Lee KW; Kim DY; Yun T; Kim DW; Kim TY; Yoon SS; Heo DS; Bang YJ; Park S; Kim BK; Kim NK
Cancer; 2003 Dec; 98(12):2651-6. PubMed ID: 14669285
[TBL] [Abstract][Full Text] [Related]
7. High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?
George A; Tam CS; Seymour JF
Leuk Lymphoma; 2013 Dec; 54(12):2575-6. PubMed ID: 23597141
[No Abstract] [Full Text] [Related]
8. [Picture in clinical hematology].
Hatsuse M; Shimazaki C; Yumiba T
Rinsho Ketsueki; 2013 Jan; 54(1):1. PubMed ID: 24015417
[No Abstract] [Full Text] [Related]
9. [Vocal cord paralysis secondary to vincristine].
Nafil H; Tazi I; Mahmal L
Rev Neurol (Paris); 2012 May; 168(5):464-5. PubMed ID: 22387202
[No Abstract] [Full Text] [Related]
10. Treatment with doxorubicin-based protocol in cardiac involvement diffuse large B-cell lymphoma: A case report.
Tekinalp A; Kars TU; Dikici HZ; Yılmaz PD; Demircioğlu S; Çeneli Ö
J Oncol Pharm Pract; 2022 Mar; 28(2):449-452. PubMed ID: 34549658
[TBL] [Abstract][Full Text] [Related]
11. Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma.
Avilés A; Neri N; Castañeda C; Talavera A; Huerta-Guzmán J; González M
Med Oncol; 2002; 19(1):55-8. PubMed ID: 12025891
[TBL] [Abstract][Full Text] [Related]
12. Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria.
Rashidi A; Oak E; Carson KR; Wagner-Johnston ND; Kreisel F; Bartlett NL
Leuk Lymphoma; 2016 May; 57(5):1191-3. PubMed ID: 26397936
[No Abstract] [Full Text] [Related]
13. CHOP plus rituximab--balancing facts and opinion.
Cheson BD
N Engl J Med; 2002 Jan; 346(4):280-2. PubMed ID: 11807154
[No Abstract] [Full Text] [Related]
14. Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma.
Hosoi M; Yamamoto G; Imai Y; Kurokawa M
Ann Hematol; 2010 Feb; 89(2):207-8. PubMed ID: 19582454
[No Abstract] [Full Text] [Related]
15. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Feugier P; Van Hoof A; Sebban C; Solal-Celigny P; Bouabdallah R; Fermé C; Christian B; Lepage E; Tilly H; Morschhauser F; Gaulard P; Salles G; Bosly A; Gisselbrecht C; Reyes F; Coiffier B
J Clin Oncol; 2005 Jun; 23(18):4117-26. PubMed ID: 15867204
[TBL] [Abstract][Full Text] [Related]
16. Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome.
Boslooper K; Kibbelaar R; Storm H; Veeger NJ; Hovenga S; Woolthuis G; van Rees B; de Graaf E; van Roon E; Kluin-Nelemans HC; Joosten P; Hoogendoorn M
Leuk Lymphoma; 2014 Mar; 55(3):526-32. PubMed ID: 23734653
[TBL] [Abstract][Full Text] [Related]
17. Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.
Walter E; Schmitt T; Dietrich S; Ho A; Witzens-Harig M
Leuk Lymphoma; 2012 Nov; 53(11):2290-2. PubMed ID: 22475324
[No Abstract] [Full Text] [Related]
18. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
[TBL] [Abstract][Full Text] [Related]
19. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.
Peyrade F; Bologna S; Delwail V; Emile JF; Pascal L; Fermé C; Schiano JM; Coiffier B; Corront B; Farhat H; Fruchart C; Ghesquieres H; Macro M; Tilly H; Choufi B; Delarue R; Fitoussi O; Gabarre J; Haioun C; Jardin F
Lancet Haematol; 2017 Jan; 4(1):e46-e55. PubMed ID: 28041583
[TBL] [Abstract][Full Text] [Related]
20. Primary Cardiac Lymphoma in an Immunocompetent 71-Year-Old Man.
Montanaro C; Loiacono F; Fragasso G; De Cobelli F; Foppoli M; Margonato A
Tex Heart Inst J; 2015 Dec; 42(6):561-4. PubMed ID: 26664312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
